Management of XXXX with pleuroperitoneal shunting.

@entity1 @entity1353 @entity189 @entity158 @entity3483
@entity3483 are often debilitating conditions for the @entity1 with advanced @entity189 . Traditionally, treatment has been repeated thoracentesis or tube thoracostomy with instillation of sclerosing agents. However, this required the @entity1 to be hospitalized and to have @entity158 and inconveniences of the chest tubes. The drainage also had to be low enough for sclerotherapy to be effective. In 1982, the pleuroperitoneal shunt became a feasible alternative to sclerotherapy. We began using the Denver pleuroperitoneal shunt in July 1991. Twenty shunts were inserted into 19 @entity1 during a two year period ending June 30, 1993. All @entity1 but one were relieved of @entity1353 . The mean duration of patency was 26 months and fewer than 25 percent of the shunts clotted before the death of the @entity1 . Our favorable experience with the shunt has resulted in us recommending the Denver pleuroperitoneal shunt for treatment of recurrent @entity3483 and selectively as primary treatment.
